The following therapeutic domains and patient-oriented benefits are commonly associated with this medication.

Primary Therapeutic Uses

The medicine is relevant in three key contexts: managing folate deficiency anemia (a condition presenting with symptoms related to systemic imbalance), playing a role in managing the risk of neural tube defects (a preventative use in early gestation), and providing supportive symptomatic relief for patients taking methotrexate.

Main Symptom Domains and Benefit

In clinical settings that involve acute or unstable symptom patterns, this medication is applied across domains where additional symptomatic support is needed. It helps address symptom clusters that may become intense or disruptive, such as the fatigue and weakness associated with anemia. It contributes to easing the overall symptom load when symptoms arise from systemic imbalance, assists with maintaining functional stability, and helps improve day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Anemia-Related Fatigue

Supportive Benefit

For preventative use, the benefit is: “It offers supportive relief that helps with the proper early development of the fetus and supports general well-being.” For patients using methotrexate, it may help patients cope more steadily with symptom fluctuations during the primary therapeutic course.

Who Can and Cannot Use Фолацин?

The population eligibility for Фолацин (Folic Acid) is strictly defined by regulatory documents, emphasizing critical contraindications and age-group approvals.

---

Contraindications and Restrictions

The medicine is contraindicated for patients with a known hypersensitivity to Folic Acid or any component of the formulation. The most critical restriction is the absolute prohibition of use in individuals with untreated megaloblastic anemia due to a Vitamin B12 deficiency. Using Folic Acid alone in this scenario can mask the blood symptoms while irreversible neurological damage progresses. Use requires caution in patients with undiagnosed anemia until a Vitamin B12 deficiency has been officially ruled out.

Permitted Populations

Eligibility Group	Status (Regulatory Basis)
Age Groups (Adults, Children, Adolescents)	Established and Permitted for deficiency treatment.
Pregnancy	Permitted for deficiency treatment and for prophylaxis of neural tube defects.
Lactation (Breastfeeding)	Permitted; considered acceptable for use.
Geriatric Patients	Permitted; use follows standard adult eligibility.

Eligibility is also conditional for patients with conditions like folate-dependent tumors and requires caution. Additionally, the tablet formulation is restricted for patients with rare hereditary disorders like Lapp lactase deficiency.

The documented interaction profile for Folic Acid is defined by specific regulatory constraints concerning co-administered medicines and substances.

---

Contraindicated Use

Folic Acid is formally contraindicated as sole therapy for undiagnosed anemia or confirmed Vitamin B12 deficiency. This regulatory restriction exists because Folic Acid may mask the hematologic manifestations while allowing the progression of irreversible neurological damage.

Drug–Drug Interactions

Interactions are documented with several classes:

• Anticonvulsants: Folic Acid is documented to exert pharmacodynamic antagonism against the antiepileptic action of agents like Phenytoin and Primidone, potentially requiring adjustment of the anticonvulsant regimen.
• Absorption Inhibitors: Medicines such as Sulphasalazine and Triamterene officially inhibit the absorption of Folic Acid, which can lead to reduced exposure.
• Folate Antagonists: Agents like Methotrexate and Trimethoprim are known to interfere with folate metabolism.

Product–Substance Interactions

• Antacids: Products containing aluminium or magnesium require a two-hour separation interval from Folic Acid administration to prevent interference with absorption.
• Ethanol: Chronic consumption of alcohol is documented to reduce intestinal absorption and increase the elimination of Folic Acid.

How Фолацин Works

Фолацин (Folic Acid) exerts its effect by serving as a precursor molecule required for the body’s fundamental metabolic and synthesis pathways. Its mechanism is strictly defined by supplying the necessary cofactors for cellular processes.

---

Enzymatic Activation and Deoxythymidylate Synthesis

The synthetic folic acid molecule must first be converted into its biologically active forms, primarily tetrahydrofolate (THF), through a reduction reaction catalyzed by the enzyme dihydrofolate reductase (DHFR). The resulting THF derivatives then function as essential carbon unit donors for nucleotide synthesis. Specifically, 5,10-methylenetetrahydrofolate is required by thymidylate synthase to generate dTMP, a crucial building block of DNA. This molecular action enables DNA synthesis to proceed appropriately, which is required for appropriate cellular morphology and division in hematopoietic cells.

---

Regulation of One-Carbon Metabolism and Homocysteine Remethylation

Active derivatives are central to the one-carbon metabolism pathway, facilitating the transfer of single carbon units. This provides the necessary cofactor to execute the homocysteine remethylation cycle, a component of amino acid metabolism. Specifically, 5-methyltetrahydrofolate is used with Vitamin B12 (cobalamin) to convert homocysteine, a metabolic intermediate, back into methionine via the enzyme methionine synthase. This action facilitates cellular methylation processes, which are required for gene expression and protein activity.

---

Mechanism Constraints: B12 Interdependency

The functionality of the folate cycle is biologically constrained by the presence of Vitamin B12. The folate derivative 5-methyltetrahydrofolate can only be recycled back into the main THF pool through a reaction strictly dependent on B12. If B12 is deficient, the mechanism results in the "folate trap," where folate is metabolically sequestered in the 5-methyl form. This failure to regenerate the main THF cofactor pool prevents the full operation of the DNA synthesis mechanism.

Фолацин (Folic Acid) is administered according to established regimens for correcting or preventing folate deficiency. The administration method may be oral via tablets, which is the standard route, or parenteral (intramuscular, intravenous, or subcutaneous injection). Parenteral delivery is reserved for situations where the oral intake is not feasible, such as cases of impaired gastrointestinal absorption.

Dosing patterns vary significantly based on the clinical context. For established adult deficiency, the therapeutic dose typically involves 1 mg administered once daily. However, in conditions involving severe malabsorption or high metabolic utilization, the required dose may be increased, with doses reaching up to 15 mg daily. The frequency of use is predominantly once daily for both therapeutic and maintenance regimens.

Usage is structured over time, with therapy often consisting of a defined course length. For correcting megaloblastic anemia, a course may last for approximately four months or until the blood picture has fully normalized. For high-risk preventative use, such as for the prophylaxis of Neural Tube Defects, higher doses (e.g., 4 mg to 5 mg daily) are initiated before conception and continued throughout the first trimester. A key procedural constraint requires that doses exceeding 0.1 mg daily must not be initiated until a deficiency in Vitamin B12 has been ruled out, a step intended to ensure proper administration. Dosing is also adjusted for specific populations, including pregnant individuals who require a higher daily maintenance dose of 0.8 mg.

Research Evidence Overview of Studies for Фолацин (Folic Acid)

---

Evidence for Correcting Folate Deficiency Anemia

Research exploring the use of Folic Acid for megaloblastic anemia, a condition characterized by systemic or functional imbalance due to low folate, primarily relies on historical clinical studies, analyses of patient data, and case series. This research was conducted to examine the medicine's administration to adults and children with confirmed deficiency. Findings generally document patterns of shift toward normal ranges in blood cell parameters and monitoring of symptomatic markers like fatigue.

Research on Preventing Neural Tube Defects

The research base that explored the link between Folic Acid and the incidence of Neural Tube Defects (NTDs), such as Spina Bifida, is built upon large-scale studies, including Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies monitored women of childbearing age during the crucial periconceptional period. Findings describe patterns related to a lower incidence of NTDs in supplemented populations. Evidence describes a link between increased maternal Red Blood Cell folate concentration and the findings observed regarding NTD rates.

Supportive Use Research Alongside Methotrexate

Folic Acid was evaluated in studies for its supportive use in adult patients receiving low-dose, weekly treatment with the medication methotrexate (MTX) for chronic inflammatory conditions. Randomized Controlled Trials and systematic reviews explored whether supplementation was associated with certain adverse events. Findings describe patterns of reduced reporting of certain adverse events, especially gastrointestinal and oral symptoms, in groups that were supplemented.

---

Main Research Gaps and Remaining Uncertainties

Research has explored various aspects of Folic Acid use, but certain clinical questions remain uncertain. There is still limited information regarding the need for specific, individualized dosing schedules. The evidence quality varies across applications, particularly between modern RCTs for NTD prevention and the older historical data for anemia correction. Furthermore, follow-up durations were limited in specific trial settings, meaning evidence is limited regarding the maintenance of functional outcomes across many years.

Key Studies & References Folic acid and prevention of neural tube defects (UK NICE Guideline CG62, updated 2021)

Common questions about Фолацин (FAQ)

---

Q: What is the difference between Folic Acid and Folate?

Folic acid and folate are both forms of Vitamin B9. According to official health authorities, Folic Acid is the synthetic version primarily used in supplements and for fortifying foods. In contrast, folate is the term used to describe the form of Vitamin B9 that occurs naturally in various foods.

---

Q: Is it possible to take this medicine by injection instead of tablets?

Yes. Official product information states that this medicine is manufactured in two primary pharmaceutical forms. It is available as tablets for oral use and also as a solution for injection. The injectable form allows for what is known as parenteral administration, meaning it is administered via injection rather than being taken by mouth.

---

Q: What is the 'folate trap' and how is it related to B12 deficiency?

The term 'folate trap' relates to a critical safety warning found in regulatory documentation regarding Vitamin B12 deficiency. Official labeling mandates that B12 deficiency must be ruled out before taking higher doses of Folic Acid. This restriction is necessary because Folic Acid can correct the blood-related symptoms of a B12 deficiency, which can mask the underlying condition and allow irreversible nerve damage to progress.

---

Q: What is the maximum dose of Folic Acid that an adult can take daily?

Regulatory documents indicate that official schedules define maximum daily requirements for adults. In conditions involving high metabolic use or severe malabsorption, the maximum dose is stated as up to 15 mg daily.

---

Q: What should I do if I miss a dose of the tablets?

Patient information leaflets often state that if a dose is missed, it can be taken as soon as the patient remembers. However, if the time for the next scheduled dose is near, the patient information typically recommends skipping the missed dose and returning to the regular dosing schedule. Official guidance cautions against taking a double dose to compensate for a single missed dose.

How to Store and Dispose of Folic Acid (Фолацин)

Folic Acid, the active substance in Фолацин, must be stored according to regulatory labeling to maintain its stability.

Official Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature, typically 20 C to 25 C.
Protection	Protect from light and moisture. Keep container tightly closed and in the original packaging.
Safety	Keep this medicine out of the sight and reach of children.

Disposal

Do not flush unused or expired tablets down the toilet. Disposal must follow local requirements for medicinal waste, often through a drug take-back program. Used needles, syringes, and vials from the injectable form must be discarded as medical sharps in a designated puncture-resistant container.